Biosynthetic advance could halve the cost of widely used cancer drug
The demand for the widely used cancer drug Taxol is increasing, but it's difficult and expensive to produce because it hasn't been possible to do it biosynthetically. Until now, that is. Researchers from the University of Copenhagen have cracked the last part of a code that science has struggled with for 30 years. The breakthrough could halve the price of the drug and make production far more sustainable.
The demand for the widely used cancer drug Taxol is increasing, but it's difficult and expensive to produce because it hasn't been possible to do it biosynthetically. Until now, that is. Researchers from the University of Copenhagen have cracked the last part of a code that science has struggled with for 30 years. The breakthrough could halve the price of the drug and make production far more sustainable.
